Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication

International Journal of Neuropsychopharmacology

Volumn 10, Issue 3, 2007, Pages 321-333

  Strous, Rael D ^a   Greenbaum, Lior ^b   Kanyas, Kyra ^b   Merbl, Yifat ^c   Horowitz, Anat ^c   Karni, Osnat ^b   Viglin, Dina ^a   Olender, Tsviya ^c   Deshpande, Smita N ^d   Lancet, Doron ^c   Ben Asher, Edna ^c   Lerer, Bernard ^b  

^a BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

Dopamine receptor interacting proteins; NEF3; NF M; Pharmacogenetics; Risperidone; Schizophrenia; Typical antipsychotics

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOTIAPINE; DOPAMINE 1 RECEPTOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PENFLURIDOL; PERPHENAZINE; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE RECEPTOR INTERACTING PROTEIN GENE; DRUG RECEPTOR BINDING; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEF3 GENE; NEUROFILAMENT; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 34247860699     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706006651     Document Type: Article

References (63)

1. Abi-Dargham A, Laruelle M (2005). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20, 15-27.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA 97, 8104-8109.
3. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228-1235.
4. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, et al. (2000). Pharmacogenetic prediction of clozapine response. Lancet 355, 1615-1616.
5. Bai J, He F, Novikova SI, Undie AS, Dracheva S, Haroutunian V, Lidow MS (2004). Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biological Psychiatry 56, 427-440.
6. Barnes TR (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
7. 2+ connection in dopamine signaling. Trends in Pharmacological Science 24, 486-492.
8. Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, O'Donovan MC (2005). Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Human Molecular Genetics 14, 1947-1954.
9. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 41, 237-260.
10. Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
11. Dahmen N, Muller MJ, Germeyer S, Rujescu D, Anghelescu I, Hiemke C, Wetzel H (2001). Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophrenia Research 49, 223-225.
12. Emsley RA, Oosthuizen PP, Toubert AF, Hawkridge SM, Stein DJ (1999). Treatment of schizophrenia in low income countries. International Journal Neuropsychopharmacology 2, 321-325.
13. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomography analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
14. First MB, Spitzer RL, Gibbon M, Williams JBW (1994). Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research.
15. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al. (2002). The structure of haplotype blocks in the human genome. Science 296, 2225-2229.
16. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health.
17. Han F, Bulman DE, Panisset M, Grimes DA (2005). Neurofilament M gene in a French-Canadian population with Parkinson's disease. Canadian Journal of Neurological Sciences 32, 68-70.
18. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke-Iqbal I, Wang JZ (2002). Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neuroscience Letters 320, 156-160.
19. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA (1995). Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121, 309-316.
20. Kay S, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale for schizophrenia. Schizophrenia Bulletin 13, 261-276.
21. Kim OJ, Ariano MA, Lazzarini RA, Levine MS, Sibley DR (2002). Neurofilament-M interacts with the D1 dopamine receptor to regulate cell surface expression and desensitization. Journal of Neuroscience 22, 5920-5930.
22. Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS (2003a). Upregulation of the d1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Archives of General Psychiatry 60, 311-319.
23. Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic PS, Lidow MS (2003b). Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proceedings of the National Academy of Sciences USA 100, 313-317.
24. Kohn Y, Ebstein RP, Heresco-Levy U, Shapira B, Nemanov L, Gritsenko I, Avnon M, Lerer B (1997). Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. European Neuropsychopharmacology 7, 39-43.
25. Kruger R, Fischer C, Schulte T, Strauss KM, Muller T, Woitalla D, Berg D, Hungs M, Gobbele R, Berger K, et al. (2003). Mutation analysis of the neurofilament M gene in Parkinson's disease. Neuroscience Letters 351, 125-129.
26. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH (2002). Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. American Journal of Psychiatry 159, 1593-1595.
27. Lariviere RC, Julien JP (2004). Functions of intermediate filaments in neuronal development and disease. Journal of Neurobiology 58, 131-148.
28. Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH (2002). A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neuroscience Letters 322, 57-61.
29. Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ (2004). Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines. American Journal of Psychiatry 161, 1848-1855.
30. Lerer B (ed.) (2002). Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
31. Lerer B, Macciardi F (2002). Pharmacogenetics of antidepressant and mood stabilising drugs: a review of candidate gene studies and future research directions. International Journal of Neuropsychopharmacology 5, 255-275.
32. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, et al. (2002). Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27, 105-119.
33. Lerer B, Segman RH, Tan E-C, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, et al. (2005). Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. International Journal of Neuropsychopharmacology 8, 411-425.
34. Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993). Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112, 40-54.
35. Lezcano N, Mrzljak L, Eubanks S, Levenson R, Goldman-Rakic P, Bergson C (2000). Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. Science 287, 1660-1664.
36. Lidow MS, Williams GV, Goldman-Rakic PS (1998). The cerebral cortex: a case for a common site of action of antipsychotics. Trends in Pharmacological Science 19, 136-40.
37. Little DP, Braun A, Darnhofer-Demar B, Frilling A, Li Y, McIver Jr. RT, Koster H (1997a). Detection of RET proto-oncogene codon 634 mutations using mass spectrometry. Journal of Molecular Medicine 75, 745-750.
38. Little DP, Braun A, Darnhofer-Demar B, Koster H (1997b). Identification of apolipoprotein E polymorphisms using temperature cycled primer oligo base extension and mass spectrometry. European Journal of Clinical Chemistry and Clinical Biochemistry 35, 545-548.
39. Ludemann N, Clement A, Hans VH, Leschik J, Behl C, Brandt R (2005). O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). Journal of Biological Chemistry 280, 31648-31658.
40. Luo X, Kranzler H, Lappalainen J, Rosenheck R, Charney D, Zuo L, Erdos J, van Kammen DP, Gelernter J (2004). CALCYON gene variation, schizophrenia, and cocaine dependence. American Journal of Medical Genetics B: Neuropsychiatry Genetics 125, 25-30.
41. Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, Breier A, Pickar D (1998). The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Molecular Psychiatry 3, 72-75.
42. Malhotra AK, Murphy Jr. GM, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 161, 780-796.
43. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nothen MM, et al. (1998). Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19, 123-132.
44. McCullough RM, Cantor CR, Ding C (2005). High-throughput alternative splicing quantification by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Nucleic Acids Research 33, e99.
45. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10, 79-104.
46. Muller DJ, Shinkai T, De Luca V, Kennedy JL (2004). Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics Journal 4, 77-87.
47. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney Jr. WE, et al. (2003). D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Molecular Psychiatry 8, 109-113.
48. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, Ganapathy V, Leibach FH (2002). Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biological Psychiatry 51, 723-732.
49. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z (2005). Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neuropsychopharmacology 15, 143-151.
50. Schäfer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ (2001). Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. American Journal of Psychiatry 158, 802-804.
51. Scharfetter J, Chaudhry HR, Hornik K, Fuchs K, Sieghart W, Kasper S, Aschauer HN (1999). Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. European Neuropsychopharmacology 10, 17-20.
52. Serretti A, Artioli P (2004). From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology 174, 490-503.
53. Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, Smith I, Gill M, Kerwin RW (1996). Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Human Genetics 97, 714-719.
54. Simpson G, Angus MP (1970). Scale for assessment extrapyramidal side effects. Acta Psychiatrica Scandanavica 212, 11-19.
55. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH (2004). Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Molecular Psychiatry 9, 433-441.
56. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW (1995). Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7, 169-172.
57. Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW (2002). Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 162, 18-23.
58. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, Kaneko S (2000). The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10, 335-41.
59. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S (2004). Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. American Journal of Psychiatry 161, 1620-1625.
60. Wang J, Tung YC, Wang Y, Li XT, Iqbal K, Grundke-Iqbal I (2001). Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Letters 507, 81-87.
61. Wiesel FA, Farde L, Nordstrom AL, Sedvall G (1990). Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 14, 759-767.
62. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L (2005). Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neuroscience Letters 376, 1-4.
63. Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D, Gothelf D, Nahshoni E, Tyano S, Weizman A (2003). DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European Neuropsychopharmacology 13, 183-185.